Tecan with strong order entry and good sales development in the second half of 2014
Tecan Group AG / Tecan with strong order entry and good sales development in the second half of 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Financial results: full-year and second half of 2014
· Order entry of CHF 417.4 million (2013: CHF 386.1 million)
o Full-year growth of 9.5% in local currencies or 8.1% in Swiss francs
o Full-year organic growth of 7.1% in local currencies or 5.7% in Swiss francs
o H2 increase of 12.2% in local currencies and Swiss francs
· Sales of CHF 399.5 million (2013: CHF 388.3 million)
o Full-year growth of 4.2% in local currencies or 2.9% in Swiss francs
o Full-year organic growth of 1.8% in local currencies or 0.5% in Swiss francs
o H2 sales growth of 10.3% in local currencies or 10.2% in Swiss francs
· Full-year operating profit
o EBIT of CHF 57.2 million (2013: CHF 54.8 million)
o EBIT margin improvement of 50 basis points to 14.6% excluding acquisition-related effects (2013: 14.1%); 14.8% assuming constant exchange rates
o EBIT margin of 14.3% including acquisition-related costs
o EBITDA margin of 16.9% (2013: 16.8%)
· Full-year net profit of CHF 40.2 million (2013: CHF 45.7 million)
o Net profit impacted by losses from currency hedging
o Earnings per share of CHF 3.63 (2013: 4.16)
· Full-year cash flow from operating activities of CHF 48.2 million (2013: CHF 27.9 million)
Operating highlights 2014 and other important information
-
Launch of Fluent(TM) laboratory automation family, Tecan's next generation liquid handling platform in the Life Sciences Business
-
Launch of ORTHO VISION(TM) Analyzer by OrthoClinical Diagnostics in the Partnering Business
-
Acquisition of IBL International, a leading immunoassay company for specialty diagnostics, to support Tecan's evolution into a solutions business
-
Unchanged dividend of CHF 1.50 per share proposed
-
Outlook 2015